(Q39620638)

English

HER2-positive breast cancer cells resistant to trastuzumab and lapatinib lose reliance upon HER2 and are sensitive to the multitargeted kinase inhibitor sorafenib

scientific article published on 9 December 2010

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

13 September 2017

HER2-positive breast cancer cells resistant to trastuzumab and lapatinib lose reliance upon HER2 and are sensitive to the multitargeted kinase inhibitor sorafenib (English)

1 reference

Europe PubMed Central

PubMed publication ID

13 September 2017

Her2-receptor positive breast cancer

0 references

1 reference

based on heuristic

inferred from title

10

0 references

Sonia Capellero

object named as

Sonia Capellero

2

0 references

Giorgio Valabrega

object named as

Giorgio Valabrega

1

0 references

Silvia Giordano

object named as

Silvia Giordano

13

0 references

Massimo Aglietta

object named as

Massimo Aglietta

14

0 references

Annalisa Petrelli

5

object named as

Annalisa Petrelli

1 reference

Europe PubMed Central

PubMed publication ID

13 September 2017

author name string

Giuliana Cavalloni

3

1 reference

Europe PubMed Central

PubMed publication ID

13 September 2017

Gianluca Zaccarello

4

1 reference

Europe PubMed Central

PubMed publication ID

13 September 2017

Giorgia Migliardi

6

1 reference

Europe PubMed Central

PubMed publication ID

13 September 2017

Andrea Milani

7

1 reference

Europe PubMed Central

PubMed publication ID

13 September 2017

Caterina Peraldo-Neia

8

1 reference

Europe PubMed Central

PubMed publication ID

13 September 2017

Loretta Gammaitoni

9

1 reference

Europe PubMed Central

PubMed publication ID

13 September 2017

Carla Pecchioni

11

1 reference

Europe PubMed Central

PubMed publication ID

13 September 2017

Aldo Moggio

12

1 reference

Europe PubMed Central

PubMed publication ID

13 September 2017

Filippo Montemurro

15

1 reference

Europe PubMed Central

PubMed publication ID

13 September 2017

language of work or name

0 references

publication date

9 December 2010

1 reference

Europe PubMed Central

PubMed publication ID

13 September 2017

Breast Cancer Research and Treatment

1 reference

Europe PubMed Central

PubMed publication ID

13 September 2017

130

1 reference

Europe PubMed Central

PubMed publication ID

13 September 2017

1

1 reference

Europe PubMed Central

PubMed publication ID

13 September 2017

29-40

1 reference

Europe PubMed Central

PubMed publication ID

13 September 2017

Untangling the ErbB signalling network

1 reference

https://api.crossref.org/works/10.1007%2FS10549-010-1281-5

21 January 2018

Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene

1 reference

https://api.crossref.org/works/10.1007%2FS10549-010-1281-5

21 January 2018

Trastuzumab: mechanism of action, resistance and future perspectives in HER2-overexpressing breast cancer.

1 reference

https://api.crossref.org/works/10.1007%2FS10549-010-1281-5

21 January 2018

Lapatinib: a dual inhibitor of EGFR and HER2 tyrosine kinase activity

1 reference

https://api.crossref.org/works/10.1007%2FS10549-010-1281-5

21 January 2018

Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: the M77001 study group

1 reference

https://api.crossref.org/works/10.1007%2FS10549-010-1281-5

21 January 2018

Lapatinib plus capecitabine for HER2-positive advanced breast cancer

1 reference

https://api.crossref.org/works/10.1007%2FS10549-010-1281-5

21 January 2018

PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients.

1 reference

https://api.crossref.org/works/10.1007%2FS10549-010-1281-5

21 January 2018

TGFalpha expression impairs Trastuzumab-induced HER2 downregulation

1 reference

https://api.crossref.org/works/10.1007%2FS10549-010-1281-5

21 January 2018

Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer

1 reference

https://api.crossref.org/works/10.1007%2FS10549-010-1281-5

21 January 2018

Combination of trastuzumab and tanespimycin (17-AAG, KOS-953) is safe and active in trastuzumab-refractory HER-2 overexpressing breast cancer: a phase I dose-escalation study

1 reference

https://api.crossref.org/works/10.1007%2FS10549-010-1281-5

21 January 2018

Trastuzumab causes antibody-dependent cellular cytotoxicity-mediated growth inhibition of submacroscopic JIMT-1 breast cancer xenografts despite intrinsic drug resistance

1 reference

https://api.crossref.org/works/10.1007%2FS10549-010-1281-5

21 January 2018

Down-regulation of myeloid cell leukemia-1 through inhibiting Erk/Pin 1 pathway by sorafenib facilitates chemosensitization in breast cancer

1 reference

https://api.crossref.org/works/10.1007%2FS10549-010-1281-5

21 January 2018

Herceptin sensitizes ErbB2-overexpressing cells to apoptosis by reducing antiapoptotic Mcl-1 expression

1 reference

https://api.crossref.org/works/10.1007%2FS10549-010-1281-5

21 January 2018

Targeting inhibitor of apoptosis proteins in combination with ErbB antagonists in breast cancer

1 reference

https://api.crossref.org/works/10.1007%2FS10549-010-1281-5

21 January 2018

The role of Mcl-1 downregulation in the proapoptotic activity of the multikinase inhibitor BAY 43-9006.

1 reference

https://api.crossref.org/works/10.1007%2FS10549-010-1281-5

21 January 2018

Effects of HER2-binding affibody molecules on intracellular signaling pathways

1 reference

https://api.crossref.org/works/10.1007%2FS10549-010-1281-5

21 January 2018

The involvement of human-nuc gene in polyploidization of K562 cell line.

1 reference

https://api.crossref.org/works/10.1007%2FS10549-010-1281-5

21 January 2018

Stable RNA interference of ErbB-2 gene synergistic with epirubicin suppresses breast cancer growth in vitro and in vivo

1 reference

https://api.crossref.org/works/10.1007%2FS10549-010-1281-5

21 January 2018

Rationale for trastuzumab (Herceptin) in adjuvant breast cancer trials

1 reference

https://api.crossref.org/works/10.1007%2FS10549-010-1281-5

21 January 2018

Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer

1 reference

https://api.crossref.org/works/10.1007%2FS10549-010-1281-5

21 January 2018

Adjuvant docetaxel or vinorelbine with or without trastuzumab for breast cancer

1 reference

https://api.crossref.org/works/10.1007%2FS10549-010-1281-5

21 January 2018

Insulin-like growth factor-I receptor/human epidermal growth factor receptor 2 heterodimerization contributes to trastuzumab resistance of breast cancer cells

1 reference

https://api.crossref.org/works/10.1007%2FS10549-010-1281-5

21 January 2018

Regulation of survivin by ErbB2 signaling: therapeutic implications for ErbB2-overexpressing breast cancers

1 reference

https://api.crossref.org/works/10.1007%2FS10549-010-1281-5

21 January 2018

A model of acquired autoresistance to a potent ErbB2 tyrosine kinase inhibitor and a therapeutic strategy to prevent its onset in breast cancer

1 reference

https://api.crossref.org/works/10.1007%2FS10549-010-1281-5

21 January 2018

Trastuzumab beyond progression in human epidermal growth factor receptor 2-positive advanced breast cancer: a german breast group 26/breast international group 03-05 study.

1 reference

https://api.crossref.org/works/10.1007%2FS10549-010-1281-5

21 January 2018

Phase II trial of sorafenib in patients with metastatic breast cancer previously exposed to anthracyclines or taxanes: North Central Cancer Treatment Group and Mayo Clinic Trial N0336.

1 reference

https://api.crossref.org/works/10.1007%2FS10549-010-1281-5

21 January 2018

Coactivation of receptor tyrosine kinases affects the response of tumor cells to targeted therapies

1 reference

https://api.crossref.org/works/10.1007%2FS10549-010-1281-5

21 January 2018

Identifiers

10.1007/S10549-010-1281-5

1 reference

Europe PubMed Central

PubMed publication ID

13 September 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

13 September 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q39620638&oldid=2203032821"